Twin Tree Management
SMMT icon

Twin Tree Management’s Summit Therapeutics SMMT Stock Holding History

Twin Tree Management’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-27,300
Closed -$564K – 1698
2025
Q3 		$564K Sell
27,300
-10,900
-29% -$264K ﹤0.01% 1264
2025
Q2 		$813K Sell
38,200
-67,400
-64% -$1.54M ﹤0.01% 1388
2025
Q1 		$2.04M Sell
105,600
-127,300
-55% -$2.55M ﹤0.01% 1144
2024
Q4 		$4.16M Buy
232,900
+194,300
+503% +$3.77M 0.01% 980
2024
Q3 		$845K Buy
+38,600
New +$540K ﹤0.01% 1248

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PCMH
Polymer Capital Management (HK) Hong Kong $1.16B AUM 135.84% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Twin Tree Management's SMMT Position: Q2 2025 in Review

Twin Tree Management sold out of Summit Therapeutics (SMMT) in Q2 2025, closing a stake of 339,085 shares — an estimated $7.73M sold.

Twin Tree Management first reported a position in SMMT in Q2 2024 and held it in 4 quarters. The position peaked at $8.85M in Q4 2024. 238 funds tracked by Wall St. Rank hold SMMT as of Q2 2025.

  • Twin Tree Management reported no remaining Summit Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Twin Tree Management sold 339,085 Summit Therapeutics shares in Q2 2025, an estimated $7.73M.
  • Twin Tree Management first reported a position in Summit Therapeutics in Q2 2024 and held it in 4 quarters.
  • Twin Tree Management's Summit Therapeutics position peaked at $8.85M in Q4 2024.
  • 238 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2025.

Based on Twin Tree Management's 13F filing for Q2 2025, filed 28 Jul 2025.